<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934282</url>
  </required_header>
  <id_info>
    <org_study_id>20160819</org_study_id>
    <nct_id>NCT02934282</nct_id>
  </id_info>
  <brief_title>HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option</brief_title>
  <official_title>Expanded Access Protocol Using HBOC-201</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mauricio Lynn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to provide treatment with HBOC-201 to patients with&#xD;
      life-threatening anemia for whom blood is not an option. Such patients may also be referred&#xD;
      to in this document as patients who refuse blood transfusion (PWRBT). Other patients who&#xD;
      potentially may require HBOC-201 treatment include those with red blood cell alloantibodies&#xD;
      for whom immunologically compatible red blood cell units cannot be found, although these&#xD;
      patients are less common than PWRBT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label intermediate-size patient population expanded access IND protocol.&#xD;
&#xD;
      Due to our experience with management of severely anemic patients for whom blood is not an&#xD;
      option, we anticipate encountering future patients with life-threatening anemia for whom&#xD;
      blood is not an option. Blood is not an option in the following circumstances:&#xD;
&#xD;
        -  refusal of transfusion&#xD;
&#xD;
        -  lack of compatible red blood cells due to alloimmunity&#xD;
&#xD;
      All patients with life-threatening anemia for whom blood is not an option will be treated as&#xD;
      per the standard procedure. If those measures are not successful and the life-threatening&#xD;
      anemia persists, then at the investigator's discretion treatment with HBOC-201 will then be&#xD;
      considered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBOC-201</intervention_name>
    <description>Hemoglobin Based Oxygen Carrier (HBOC)</description>
    <other_name>hemoglobin glutamer - 250 (bovine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients â‰¥ 18 years of age&#xD;
&#xD;
          2. Critically ill patients with hemoglobin &lt; 5 g/dL (or 6-7 g/dL with significant active&#xD;
             bleeding), and physiologic evidence of critical ischemia, for example: elevated&#xD;
             troponins, altered mental status, acute renal failure, lactic acidosis or evidence of&#xD;
             central nervous system acute deficits&#xD;
&#xD;
          3. Patients or their Legally Authorized Representative who are able and willing to&#xD;
             provide informed consent&#xD;
&#xD;
          4. Blood is not an option due to:&#xD;
&#xD;
               -  refusal of transfusion&#xD;
&#xD;
               -  lack of compatible red blood cells&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known hypersensitivity or allergy to beef products&#xD;
&#xD;
          2. Patients with pre-existing uncontrolled hypertension, heart failure, renal failure,&#xD;
             circulatory hypervolemia or systemic mastocytosis*&#xD;
&#xD;
          3. Patients who are eligible for blood transfusions&#xD;
&#xD;
          4. Patients who are &gt; 80 years old*&#xD;
&#xD;
          5. Pregnant&#xD;
&#xD;
          6. Lactating&#xD;
&#xD;
               -  on a case by case and quality of life determination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Lynn</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mauricio Lynn, MD</last_name>
    <phone>305-585-1178</phone>
    <email>mlynn@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Mauricio Lynn</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HBOC 201</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

